Management of myasthenia gravis using cyclosporine in 2 dogs

Journal of Veterinary Internal Medicine

Volumn 20, Issue 6, 2006, Pages 1487-1490

  Bexfield, Nicholas H ^a   Watson, Penny J ^a   Herrtage, Michael E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; DOG; DOG DISEASE; MALE; MYASTHENIA GRAVIS; TREATMENT OUTCOME;

ANIMALS; CYCLOSPORINE; DOG DISEASES; DOGS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYASTHENIA GRAVIS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 33845702104     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[1487:MOMGUC]2.0.CO;2     Document Type: Article

References (25)

1. Shelton GD. Myasthenia gravis and disorders of neuromuscular transmission. Vet Clin North Am Small Anim Pract 2002;32:189-206.
2. Dewey CW, Bailey CS, Shelton GD, et al. Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995). J Vet Intern Med 1997;11:50-57.
3. Shelton GD. Myasthenia gravis: Lessons from the last 10 years. J Small Anim Pract 1998;39:368-372.
4. Shelton GD, Schule A, Kass PH. Risk factors for acquired myasthenia gravis in dogs: 1,154 cases (1991-1995). J Am Vet Med Assoc 1997;211:1428-1431.
5. Shelton GD, Willard MD, Cardinet GH, Lindstrom J. Acquired myasthenia gravis: Selective involvement of esophageal, pharyngeal, and facial muscles. J Vet Intern Med 1990;4:281-284.
6. Lennon VA. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997;48:23-27.
7. Shelton GD. Acquired myasthenia gravis: What we have learned from experimental and spontaneous animal models. Vet Immunol Immunopathol 1999;69:239-249.
8. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: Disease severity and prognosis. Eur J Neurol 2005;12:413-418.
9. Penderis J. Junctionopathies of the neuromuscular junction. In Dewey CW, ed. A Practical Guide to Canine and Feline Neurology. Ames, Iowa: Blackwell Publishing; 2000:463-515.
10. Juel VC, Massey JM. Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation. Curr Treat Options Neurol 2005;7:3-14.
11. Spring PJ, Spies JM. Myasthenia gravis: Options and timing of immunomodulatory treatment. BioDrugs 2001;15:173-183.
12. Seybold ME, Drachman DB. Gradually increasing doses of prednisolone in myasthenia gravis: Reducing the hazards of treatment. N Eng J Med 1974;290:81-84.
13. Adamo FP, O'Brien RT. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. J Am Vet Med Assoc 2004;225:1211-1216.
14. Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 1997;211:1249-1253.
15. Guaguere E. Efficacy of cyclosporine in the treatment of idiopathic sterile nodular panniculitis in two dogs. Vet Dermatol 2000;11(Suppl 1):22-26.
16. Olivry T, Rivierre C, Jackson HA, et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: A blinded randomized prednisolone-controlled trial. Vet Dermatol 2002;13:77-87.
17. Steffan J, Alexander D, Brovedani F, et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel blinded randomized controlled trial. Vet Dermatol 2003;14:11-22.
18. Guaguere E, Steffan J, Olivry T. Cyclosporine A: A new drug in the field of canine dermatology. Vet Dermatol 2004;15:61-74.
19. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551.
20. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55:448-450.
21. Cahoon WD, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother 2006;40:295-298.
22. Dewey CW, Boothe DM, Rinn KL, et al. Treatment of a myasthenic dog with mycophenolate mofetil. J Vet Emerg Crit Care 2000;10:177-187.
23. Ryffel B, Donatsch P, Madorin M. Toxicological evaluation of cyclosporine A. Arch Toxicol 1983;53:107-141.
24. Drachman DB, Adams RN, McIntosh K, Pestronk A. Treatment of experimental myasthenia gravis with cyclosporine A. Clin Immunol Immunopathol 1985;34:174-188.
25. Shelton DG, Lindstrom JM. Spontaneous remission of canine myasthenia gravis: Implications for assessing human MG therapies. Neurology 2001;57:2139-2141.